Nivalis Therapeutics, Inc. (NVLS) Given Consensus Rating of “Hold” by Brokerages
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) has been given a consensus rating of “Hold” by the nine analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $6.15.
Several research firms have issued reports on NVLS. Cowen and Company restated a “hold” rating on shares of Nivalis Therapeutics in a report on Wednesday, April 19th. Vetr downgraded Nivalis Therapeutics from a “hold” rating to a “sell” rating and set a $2.50 price target for the company. in a report on Monday, February 27th. Zacks Investment Research upgraded Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, April 19th. Finally, ValuEngine downgraded Nivalis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
In other Nivalis Therapeutics news, insider Value Fund L. P. Biotechnology purchased 109,034 shares of Nivalis Therapeutics stock in a transaction on Thursday, May 11th. The stock was bought at an average price of $2.32 per share, for a total transaction of $252,958.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Robert E. Conway purchased 15,000 shares of Nivalis Therapeutics stock in a transaction on Monday, May 8th. The shares were acquired at an average price of $2.28 per share, with a total value of $34,200.00. Following the transaction, the director now directly owns 60,000 shares in the company, valued at approximately $136,800. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 440,192 shares of company stock valued at $1,011,290. 3.00% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Nivalis Therapeutics by 104.7% in the first quarter. Vanguard Group Inc. now owns 411,229 shares of the biotechnology company’s stock worth $1,201,000 after buying an additional 210,325 shares during the period. Spark Investment Management LLC raised its position in shares of Nivalis Therapeutics by 579.8% in the first quarter. Spark Investment Management LLC now owns 168,580 shares of the biotechnology company’s stock worth $492,000 after buying an additional 143,780 shares during the period. Finally, Perceptive Advisors LLC acquired a new position in shares of Nivalis Therapeutics during the fourth quarter worth about $274,000. Institutional investors own 52.96% of the company’s stock.
Shares of Nivalis Therapeutics (NASDAQ NVLS) traded up 2.73% on Monday, hitting $2.26. 68,224 shares of the stock traded hands. The firm’s 50 day moving average is $2.31 and its 200-day moving average is $2.42. The company’s market cap is $35.38 million. Nivalis Therapeutics has a 12 month low of $2.00 and a 12 month high of $9.35.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.